AltruBio
CompanyUnited States
AltruBio develops one asset, in phase 2 (ALTB-268 in ulcerative colitis). Mostly antibody; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $288M
- 0
- Trials
- 0
- Signals
Pipeline
1Activates PSGL-1 to downregulate activated T cells and reduce inflammation.
Phase 2, Antibody, ulcerative colitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants2
- Similar companies6